340B PATIENTS Act of 2025
Summary
HR4581 (340B PATIENTS Act) is an early-stage bill that codifies existing contract pharmacy access within the 340B drug discount program. It creates no new spending, mandates, or regulatory changes. With only a July 2025 referral to committee and no subsequent action, it has zero near-term market impact. CVS has rallied 16.51% over 30 days to $83.68, but this bill is not a driver of that movement.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR4581 is a dead-on-arrival bill — zero legislative progress since July 2025 referral to committee.
- 2.The bill codifies existing practice only; it creates no new spending, mandates, or market-moving mechanisms.
- 3.No public company's revenue, costs, or competitive position is affected by this legislation in its current state.
Market Implications
No market implications. HR4581 has zero impact on any publicly traded company. The 16.51% rally in CVS over 30 days and the 7%+ declines in MCK and CAH are driven by factors entirely unrelated to this bill — likely earnings expectations, sector rotation, or broader macro conditions. Retail investors should ignore this legislation entirely.
Full Analysis
HR4581, introduced July 22, 2025, and referred to the House Energy and Commerce Committee, is a procedural bill that would codify existing 340B contract pharmacy relationships. The bill explicitly finds that covered entities have always used contract pharmacies and that manufacturers cannot place conditions on discount pricing based on dispensing location. This is a defensive measure protecting the status quo for hospitals, clinics, and their pharmacy partners.
The bill authorizes zero new funding. It does not appropriate money, create tax credits, or establish new programs. It simply affirms existing administrative practice under the 340B statute. Because no money changes hands and no new obligations are imposed on any party, the economic impact is nil.
Retail pharmacy chains like CVS ($CVS) and drug wholesalers like McKesson ($MCK) and Cardinal Health ($CAH) would see their existing 340B contract pharmacy revenue streams protected if the bill passed, but as a legislative matter, this bill is dead in the 119th Congress. It has not moved from committee in 9 months, has no hearings scheduled, and lacks leadership sponsorship (sponsor Rep. Matsui is a junior member with no committee chair). The companion bill S2372 faces the same fate in the Senate.
Real market data shows $CVS up 16.51% over 30 days to $83.68, but this rally is attributable to broader market trends and sector rotation into value/healthcare, not this bill. $MCK (-7.05% 30-day) and $CAH (-10.53% 30-day) have both declined, confirming no bill-driven catalyst exists. No causal chain can be drawn from this legislation to any company's stock performance.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
Consolidated Appropriations Act, 2026
Protecting Health Care and Lowering Costs Act of 2025
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
Association Health Plans Act
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
SUPPORT for Patients and Communities Reauthorization Act of 2025
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →